The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated ...
With bispecifics, that’s extraordinarily rare. The incidence of ICANS with bispecifics is on the order of 5% or less, and ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation. The conversation examines antimicrobial stewardship and ...
Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown ...
A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...
The FDA has granted fast track designation to VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® ...
The safety profile is one of the biggest advantages of CAR NK cells, and that is exciting for the field because NK cells do ...
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as ...
Just weeks after the FDA approved an all-oral regimen for newly diagnosed acute myeloid leukemia (AML), a panel of leukemia ...
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility ...
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results